BR112017024797A2 - neoantígenos partilhados - Google Patents
neoantígenos partilhadosInfo
- Publication number
- BR112017024797A2 BR112017024797A2 BR112017024797-6A BR112017024797A BR112017024797A2 BR 112017024797 A2 BR112017024797 A2 BR 112017024797A2 BR 112017024797 A BR112017024797 A BR 112017024797A BR 112017024797 A2 BR112017024797 A2 BR 112017024797A2
- Authority
- BR
- Brazil
- Prior art keywords
- subjects
- tumor specific
- tumor
- population
- neoantigenic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001104—Epidermal growth factor receptors [EGFR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
- A61K39/001151—Apoptosis related proteins, e.g. survivin or livin p53
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001152—Transcription factors, e.g. SOX or c-MYC
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001162—Kinases, e.g. Raf or Src
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001164—GTPases, e.g. Ras or Rho
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001196—Fusion proteins originating from gene translocation in cancer cells
- A61K39/001197—Breakpoint cluster region-abelson tyrosine kinase [BCR-ABL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/34—Allele or polymorphism specific uses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7023—(Hyper)proliferation
- G01N2800/7028—Cancer
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562179877P | 2015-05-20 | 2015-05-20 | |
| US62/179,877 | 2015-05-20 | ||
| US201662389377P | 2016-02-23 | 2016-02-23 | |
| US62/389,377 | 2016-02-23 | ||
| PCT/US2016/033452 WO2016187508A2 (en) | 2015-05-20 | 2016-05-20 | Shared neoantigens |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112017024797A2 true BR112017024797A2 (pt) | 2018-08-07 |
Family
ID=56203902
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017024797-6A BR112017024797A2 (pt) | 2015-05-20 | 2016-05-20 | neoantígenos partilhados |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US10835585B2 (https=) |
| EP (1) | EP3297660A2 (https=) |
| JP (3) | JP6913032B2 (https=) |
| KR (2) | KR20180010229A (https=) |
| CN (2) | CN116196401A (https=) |
| AU (3) | AU2016264623B2 (https=) |
| BR (1) | BR112017024797A2 (https=) |
| CA (1) | CA2986235A1 (https=) |
| CL (2) | CL2017002945A1 (https=) |
| CO (1) | CO2017012835A2 (https=) |
| CR (3) | CR20200476A (https=) |
| EC (1) | ECSP17084137A (https=) |
| HK (1) | HK1252267A1 (https=) |
| IL (3) | IL255769B2 (https=) |
| MX (3) | MX2017014700A (https=) |
| MY (1) | MY190974A (https=) |
| PE (1) | PE20180670A1 (https=) |
| PH (1) | PH12017502321A1 (https=) |
| RU (1) | RU2733754C2 (https=) |
| TW (3) | TW202523682A (https=) |
| WO (1) | WO2016187508A2 (https=) |
Families Citing this family (214)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2350075E (pt) | 2008-09-22 | 2014-06-09 | Array Biopharma Inc | Compostos imidazo[1,2b]piridazina substituídos como inibidores da trk cinase |
| AR074052A1 (es) | 2008-10-22 | 2010-12-22 | Array Biopharma Inc | Compuestos pirazolo{1,5-a}pirimidina sustituida como inhibidores de trk cinasa |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| NZ604708A (en) | 2010-05-20 | 2015-05-29 | Array Biopharma Inc | Macrocyclic compounds as trk kinase inhibitors |
| WO2015077717A1 (en) | 2013-11-25 | 2015-05-28 | The Broad Institute Inc. | Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status |
| WO2015085147A1 (en) | 2013-12-05 | 2015-06-11 | The Broad Institute Inc. | Polymorphic gene typing and somatic change detection using sequencing data |
| EP3082853A2 (en) | 2013-12-20 | 2016-10-26 | The Broad Institute, Inc. | Combination therapy with neoantigen vaccine |
| HUE061448T2 (hu) | 2014-11-16 | 2023-07-28 | Array Biopharma Inc | (S)-N-(5-((R)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-A]pirimidin-3-il) -3-hidroxipirrolidin-1-karboxamid-hidrogénszulfát kristályos formája |
| US10975442B2 (en) | 2014-12-19 | 2021-04-13 | Massachusetts Institute Of Technology | Molecular biomarkers for cancer immunotherapy |
| US10993997B2 (en) | 2014-12-19 | 2021-05-04 | The Broad Institute, Inc. | Methods for profiling the t cell repertoire |
| TW202523682A (zh) * | 2015-05-20 | 2025-06-16 | 美商博德研究所有限公司 | 共有之gata3相關之腫瘤特異性新抗原 |
| CN108697708A (zh) | 2015-10-26 | 2018-10-23 | 洛克索肿瘤学股份有限公司 | Trk抑制剂抗性癌症中的点突变以及与此相关的方法 |
| RU2729116C2 (ru) | 2015-12-16 | 2020-08-04 | Гритстоун Онколоджи, Инк. | Идентификация, производство и применение неоантигенов |
| US20190022239A1 (en) * | 2016-01-19 | 2019-01-24 | The University Of Western Australia | Novel biomolecule conjugates and uses therefor |
| US20170224796A1 (en) | 2016-02-05 | 2017-08-10 | Xeme Biopharma Inc. | Therapeutic Cancer Vaccine Containing Tumor-Associated Neoantigens and Immunostimulants in a Delivery System |
| JP2019513021A (ja) | 2016-03-24 | 2019-05-23 | ナントセル，インコーポレイテッド | ネオエピトープ提示のための配列の配置および配列 |
| FI3436048T3 (fi) * | 2016-03-31 | 2025-09-15 | Biontech Us Inc | Neoantigeeneja ja niiden käyttömenetelmiä |
| ES2987474T3 (es) | 2016-04-04 | 2024-11-15 | Loxo Oncology Inc | Formulaciones líquidas de (S)-N-(5-((R)-2-(2,5-difluorofenil)-pirrolidin-1-IL)-pirazolo[1,5-A]pirimidin-3-IL)-3-hidroxipirrolidina-1-carboxamida |
| US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
| CA3056212A1 (en) * | 2016-04-07 | 2017-10-12 | Bostongene Corporation | Construction and methods of use of a therapeutic cancer vaccine library comprising fusion-specific vaccines |
| WO2017190218A1 (en) * | 2016-05-06 | 2017-11-09 | University Health Network | Liquid-biopsy signatures for prostate cancer |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| ES2836222T3 (es) | 2016-05-18 | 2021-06-24 | Loxo Oncology Inc | Preparación de (S)-N-(5-((R)-2-(2,5-difluorofenil)pirrolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida |
| JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
| WO2018094569A1 (zh) * | 2016-11-22 | 2018-05-31 | 深圳华大基因研究院 | 多肽及其应用 |
| CN109952308B (zh) * | 2016-11-29 | 2022-09-23 | 武汉华大吉诺因生物科技有限公司 | 多肽及其应用 |
| CA3045811A1 (en) | 2016-12-01 | 2018-06-07 | Nantomics, Llc | Tumor antigenicity processing and presentation |
| CA3049961A1 (en) | 2016-12-09 | 2018-06-14 | The Broad Institute, Inc. | Crispr effector system based diagnostics |
| CN118271442A (zh) | 2016-12-23 | 2024-07-02 | 蓝鳍生物医药公司 | 抗sez6l2抗体和抗体药物缀合物 |
| US20190343951A1 (en) * | 2017-01-13 | 2019-11-14 | National Research Council Of Canada | Method of optimizing peptide immuno-epitope by glycosylation, optimized peptide thereof and its use for conjugate vaccines |
| ES2928773T3 (es) | 2017-01-17 | 2022-11-22 | Heparegenix Gmbh | Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos |
| WO2018136664A1 (en) * | 2017-01-18 | 2018-07-26 | Ichan School Of Medicine At Mount Sinai | Neoantigens and uses thereof for treating cancer |
| WO2018140391A1 (en) | 2017-01-24 | 2018-08-02 | The Broad Institute, Inc. | Compositions and methods for detecting a mutant variant of a polynucleotide |
| JP2020514321A (ja) | 2017-02-01 | 2020-05-21 | モデルナティーエックス， インコーポレイテッド | 活性化がん遺伝子変異ペプチドをコードする免疫調節治療ｍＲＮＡ組成物 |
| WO2018145020A1 (en) * | 2017-02-03 | 2018-08-09 | The Medical College Of Wisconsin, Inc. | Kras peptide vaccine compositions and method of use |
| CN106868133A (zh) * | 2017-02-24 | 2017-06-20 | 北京致成生物医学科技有限公司 | 一种监测肿瘤发生发展的产品及其应用 |
| US11174515B2 (en) | 2017-03-15 | 2021-11-16 | The Broad Institute, Inc. | CRISPR effector system based diagnostics |
| CN111108220B (zh) | 2017-03-15 | 2024-11-19 | 博德研究所 | 用于病毒检测的基于crispr效应系统的诊断 |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| CN108659114B (zh) * | 2017-04-01 | 2022-10-21 | 中国科学院广州生物医药与健康研究院 | 识别pasd1抗原短肽的tcr |
| US12303561B2 (en) | 2017-04-03 | 2025-05-20 | Biontech Us Inc. | Protein antigens and uses thereof |
| IL314202B1 (en) * | 2017-04-24 | 2026-04-01 | Nantcell Inc | Neoepitope vectors and methods for them |
| MX2019013259A (es) | 2017-05-08 | 2020-01-13 | Gritstone Oncology Inc | Vectores de neoantigeno de alfavirus. |
| WO2018209015A1 (en) * | 2017-05-10 | 2018-11-15 | University Of Connecticut | Dendritic cells as a novel delivery system for immunotherapy |
| EP3622092A4 (en) | 2017-05-11 | 2021-06-23 | The Broad Institute, Inc. | METHODS AND COMPOSITIONS OF USE OF CD8 + TUMOR-INFILTRATING LYMPHOCYTE SUBTYPES AND GENE SIGNATURES THEREOF |
| US11807662B2 (en) | 2017-05-16 | 2023-11-07 | The Johns Hopkins University | MANAbodies and methods of using |
| KR20240113607A (ko) | 2017-06-21 | 2024-07-22 | 트랜스진 | 개인 맞춤형 백신 |
| AU2018287169B2 (en) * | 2017-06-22 | 2024-11-14 | Neogap Therapeutics Ab | T-cell expansion method and uses |
| NL2019156B1 (en) * | 2017-06-30 | 2019-01-10 | Academisch Ziekenhuis Leiden H O D N Leids Univ Medisch Centrum | Treatment of haematological malignancies |
| US11352389B2 (en) | 2017-06-30 | 2022-06-07 | Academisch Ziekenhuis Leiden (H.O.D.N. Leids Universitair Medisch Centrum) | Treatment of haematological malignancies |
| US20220305102A1 (en) * | 2017-06-30 | 2022-09-29 | Academisch Ziekenhuis Leiden (H.O.D.N. Leids Universitair Medisch Centrum) | Treatment of haematological malignancies |
| CN107325171A (zh) * | 2017-07-06 | 2017-11-07 | 江苏迈健生物科技发展股份有限公司 | 抗原肽t790m‑7及其在制备治疗非小细胞肺癌的药物中的应用 |
| CN107188955A (zh) * | 2017-07-06 | 2017-09-22 | 江苏迈健生物科技发展股份有限公司 | 抗原肽t790m‑3及其在制备治疗非小细胞肺癌的药物中的应用 |
| CR20200059A (es) * | 2017-07-07 | 2020-06-01 | Immatics Biotechnologies Gmbh | Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de pulmón, incluyendo el nsclc, el sclc y otros cánceres |
| HUE061840T2 (hu) * | 2017-07-12 | 2023-08-28 | Nouscom Ag | Egy univerzális vakcina, amely közös tumor neoantigéneken alapul a mikroszatellita-instabilitás (MSI) rákos megbetegedések megelõzésére és kezelésére |
| US12049643B2 (en) | 2017-07-14 | 2024-07-30 | The Broad Institute, Inc. | Methods and compositions for modulating cytotoxic lymphocyte activity |
| CN110997903B (zh) * | 2017-08-10 | 2024-03-29 | 古德T细胞有限公司 | 用于癌症治疗的t细胞的活化方法 |
| JP7763588B2 (ja) * | 2017-09-05 | 2025-11-04 | グリットストーン バイオ インコーポレイテッド | Ｔ細胞療法用の新生抗原の特定法 |
| CN111566213B (zh) | 2017-09-11 | 2023-08-04 | 国立大学法人北海道大学 | 癌症治疗药物 |
| EA202090757A1 (ru) * | 2017-09-29 | 2020-08-21 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез | T-КЛЕТОЧНЫЕ РЕЦЕПТОРЫ, РАСПОЗНАЮЩИЕ МУТАНТНЫЙ p53 |
| KR20260039788A (ko) | 2017-10-10 | 2026-03-20 | 시애틀 프로젝트 코포레이션 | 핫스팟을 이용한 신생항원 동정 |
| AU2018350990A1 (en) * | 2017-10-18 | 2020-05-21 | Regenxbio Inc. | Treatment of ocular diseases and metastatic colon cancer with human post-translationally modified VEGF-Trap |
| CA3083097A1 (en) | 2017-11-22 | 2019-05-31 | Gritstone Oncology, Inc. | Reducing junction epitope presentation for neoantigens |
| US11793867B2 (en) | 2017-12-18 | 2023-10-24 | Biontech Us Inc. | Neoantigens and uses thereof |
| BR112020015093A2 (pt) | 2018-01-29 | 2020-12-08 | The Broad Institute, Inc. | Diagnóstico baseado no sistema de efetor crispr |
| EP4036235A1 (en) * | 2018-02-15 | 2022-08-03 | National University Corporation Asahikawa Medical University | Cancer antigen peptide |
| US20210238690A1 (en) * | 2018-04-26 | 2021-08-05 | Intellexon Gmbh | Hla-j and medical/diagnostic uses thereof |
| US12577286B2 (en) * | 2018-05-01 | 2026-03-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors which recognize mutated EGFR |
| WO2019217837A1 (en) * | 2018-05-11 | 2019-11-14 | Memorial Sloan-Kettering Cancer Center | T cell receptors targeting pik3ca mutations and uses thereof |
| CN108588201B (zh) * | 2018-05-11 | 2019-08-09 | 浙江省人民医院 | 一种结直肠癌西妥昔单抗耐药性痕量dna突变检测的方法及装置 |
| CN112941155B (zh) * | 2018-05-14 | 2023-07-14 | 北京艾克伦医疗科技有限公司 | 具有茎环结构的dna引物对及其应用 |
| CN112368386A (zh) * | 2018-05-23 | 2021-02-12 | 磨石肿瘤生物技术公司 | 共有抗原 |
| US12528848B2 (en) | 2018-05-25 | 2026-01-20 | The Wistar Institute Of Anatomy And Biology | Tumor-specific neoantigens and methods of using the same |
| CN108728529B (zh) * | 2018-06-06 | 2020-08-04 | 青岛泱深生物医药有限公司 | Znf770基因在制备诊治子痫前期的产品中的应用 |
| CN110577953B (zh) * | 2018-06-11 | 2024-02-20 | 深圳华大生命科学研究院 | 基因突变体及其应用 |
| CN109142729B (zh) * | 2018-06-14 | 2021-04-23 | 郑州大学第一附属医院 | 一种肺癌标志物抗-hmgb3自身抗体及其应用 |
| ES3021225T3 (en) * | 2018-06-18 | 2025-05-26 | College France | Ligand controling interaction between gags with their effector molecules and use thereof |
| BR112020025764A2 (pt) * | 2018-06-19 | 2021-05-11 | Biontech Us Inc. | neoantígenos e usos dos mesmos |
| KR20210040355A (ko) * | 2018-06-19 | 2021-04-13 | 바이오엔테크 유에스 인크. | 네오항원 및 이의 용도 |
| GB201810358D0 (en) * | 2018-06-25 | 2018-08-08 | Univ College Cardiff Consultants Ltd | Cancer-specific t-cell receptors |
| CA3106567A1 (en) | 2018-07-26 | 2020-01-30 | Frame Pharmaceuticals B.V. | Cancer vaccines for kidney cancer |
| CA3106574A1 (en) * | 2018-07-26 | 2020-01-30 | Frame Pharmaceuticals B.V. | Arid1a, cdkn2a, kmt2b, kmt2d, tp53 and pten vaccines for cancer |
| WO2020022901A1 (en) | 2018-07-26 | 2020-01-30 | Frame Pharmaceuticals B.V. | Cancer vaccines for uterine cancer |
| EP3827263A1 (en) | 2018-07-26 | 2021-06-02 | Frame Pharmaceuticals B.V. | Cancer vaccines for colorectal cancer |
| CA3106562A1 (en) | 2018-07-26 | 2020-01-30 | Frame Pharmaceuticals B.V. | Off-the-shelf cancer vaccines |
| WO2020022899A1 (en) | 2018-07-26 | 2020-01-30 | Frame Pharmaceuticals B.V. | Cancer vaccines for breast cancer |
| US12268690B2 (en) | 2018-07-27 | 2025-04-08 | Oregon Health & Science University | Treatments for mutations in acute myeloid leukemia |
| TW202019955A (zh) | 2018-07-31 | 2020-06-01 | 德商英麥提克生物技術股份有限公司 | B*07 限制肽和肽組合的抗癌免疫治療和相關方法 |
| US20250046393A9 (en) * | 2018-08-28 | 2025-02-06 | CeCaVa GmbH & Co. KG | Methods for ranking and/or selecting tumor-specific neoantigens |
| JP2021536239A (ja) * | 2018-08-28 | 2021-12-27 | ロシュ イノベーション センター コペンハーゲン エーエス | スプライス調節化合物を使用したネオアンチゲン操作 |
| JP7598315B2 (ja) * | 2018-09-05 | 2024-12-11 | エンエーセー オンコイミュニティ アクスイェ セルスカプ | 併用療法用ｄｎａワクチンを標的とするネオアンチゲン |
| CN109022585A (zh) * | 2018-09-10 | 2018-12-18 | 路君 | Pbld基因在制备肾透明细胞癌诊断和预测预后药物中的应用 |
| KR20210062005A (ko) * | 2018-09-20 | 2021-05-28 | 다이이찌 산쿄 가부시키가이샤 | 항 her3 항체-약물 콘쥬게이트 투여에 의한 her3 변이암의 치료 |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| CN109207431B (zh) * | 2018-10-12 | 2021-10-15 | 武汉大学 | 一种抑制人癌基因STAT3的α亚型表达的方法 |
| CN109486935A (zh) * | 2018-10-18 | 2019-03-19 | 中国医学科学院北京协和医院 | 作为骨质疏松症诊治靶标的aknad1基因 |
| CN109321569B (zh) * | 2018-10-29 | 2022-04-12 | 迈杰转化医学研究(苏州)有限公司 | 一种引物探针组合物及其应用 |
| CN111116754A (zh) * | 2018-10-30 | 2020-05-08 | 天津亨佳生物科技发展有限公司 | 一种针对egfr l858r基因突变的特异性tcr及其应用 |
| WO2020092705A1 (en) * | 2018-10-31 | 2020-05-07 | University Of Virginia Patent Foundation | Self-assembling peptides and hydrogels |
| JPWO2020090979A1 (ja) * | 2018-10-31 | 2021-09-24 | 味の素株式会社 | 抗体に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩 |
| US12325880B2 (en) | 2018-11-01 | 2025-06-10 | The Broad Institute, Inc. | Identification of PDE3 modulator responsive cancers |
| CN109504771A (zh) * | 2018-11-19 | 2019-03-22 | 北京大学深圳医院（北京大学深圳临床医学院） | Adcy2作为乳腺癌的分子标记物的应用 |
| CN109438570B (zh) * | 2018-11-28 | 2021-07-20 | 生命谷（海南）生物科技股份有限公司 | 肿瘤相关基因fgfr3突变短肽及其应用 |
| CN109371026A (zh) * | 2018-12-11 | 2019-02-22 | 宁夏医科大学总医院 | 一种环状RNA hsa_circACACB_035及其特异性扩增引物和应用 |
| WO2020131586A2 (en) | 2018-12-17 | 2020-06-25 | The Broad Institute, Inc. | Methods for identifying neoantigens |
| TWI844602B (zh) | 2018-12-20 | 2024-06-11 | 美商安進公司 | Kif18a抑制劑 |
| GB201821207D0 (en) | 2018-12-24 | 2019-02-06 | Tcer Ab | Immunotherapy therapy |
| CN111363816B (zh) * | 2018-12-26 | 2024-02-02 | 广州康立明生物科技股份有限公司 | 基于pax3和zic4基因的肺癌诊断试剂及试剂盒 |
| CN109576362B (zh) * | 2018-12-28 | 2020-09-04 | 青岛泱深生物医药有限公司 | 阿尔茨海默诊治用标志物fam170a |
| TWI852977B (zh) * | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| CN109504778B (zh) * | 2019-01-11 | 2021-11-09 | 复旦大学附属中山医院 | 一种基于表观修饰的5hmC多分子标志物及结直肠癌早期诊断模型 |
| CN113573724B (zh) * | 2019-01-15 | 2025-12-19 | 康奈尔大学 | 重组润滑素和组合物以及其使用方法 |
| CN109887553B (zh) * | 2019-01-29 | 2021-01-26 | 杭州纽安津生物科技有限公司 | 针对肿瘤靶向药物耐药位点的多肽疫苗及其设计方法 |
| WO2020168047A1 (en) * | 2019-02-13 | 2020-08-20 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Combination of t-cell therapy and targeted therapy for treating therapy-resistant melanoma with mutations in the braf gene |
| SG11202109073VA (en) | 2019-02-20 | 2021-09-29 | Rubius Therapeutics Inc | Engineered erythroid cells including loadable antigen-presenting polypeptides and methods of use |
| CN109735624A (zh) * | 2019-03-14 | 2019-05-10 | 台州市立医院 | 基因标志物在甲状腺癌诊断中的应用 |
| WO2020188110A1 (en) * | 2019-03-21 | 2020-09-24 | Institute For Research In Biomedicine | Peptide inhibitors targeting the cxcl12/hmgb1 interaction and uses thereof |
| IL266728B (en) * | 2019-05-19 | 2020-11-30 | Yeda Res & Dev | Identification of recurrent mutant neopeptides |
| WO2020237208A1 (en) * | 2019-05-23 | 2020-11-26 | Christiana Care Health Services, Inc. | Gene knockout of variant nrf2 for treatment of cancer |
| MX2021014525A (es) | 2019-05-30 | 2022-03-17 | Gritstone Bio Inc | Adenovirus modificados. |
| DE102019114735A1 (de) * | 2019-06-02 | 2020-12-03 | PMCR GmbH | HLA-Tumorantigenpeptiden der Klasse I und II zur Behandlung von Mamma-/Brustkarzinomen |
| US11306122B2 (en) * | 2019-06-14 | 2022-04-19 | The United States Government As Represented By The Department Of Veterans Affairs | Compositions and methods of inhibiting the binding of plasma IgG autoantibodies to serotonin 2A receptor |
| WO2020257553A1 (en) * | 2019-06-20 | 2020-12-24 | Memorial Sloan-Kettering Cancer Center | T cell receptors targeting pik3ca mutations and uses thereof |
| CN110358827A (zh) * | 2019-07-09 | 2019-10-22 | 中国人民解放军第四军医大学 | Vmp1基因在病理诊断胶质母细胞瘤中的应用及其试剂盒的制备 |
| CN110358831B (zh) * | 2019-07-11 | 2021-12-24 | 江苏医药职业学院 | 检测跨膜蛋白41a表达水平的试剂的应用和试剂盒 |
| US12486334B2 (en) | 2019-07-12 | 2025-12-02 | The Regents Of The University Of California | Chemically controlled monoclonal antibody target engagement |
| CN114585647A (zh) * | 2019-07-16 | 2022-06-03 | 华盛顿大学 | 抗grp78抗体及其使用方法 |
| US20220265792A1 (en) * | 2019-07-30 | 2022-08-25 | Breakbio Corp. | Methods for treating solid tumors |
| MX2022001812A (es) | 2019-08-12 | 2022-03-11 | Regeneron Pharma | Variantes del receptor estimulante de macrofagos 1 (mst1r) y sus usos. |
| WO2021032779A1 (en) * | 2019-08-19 | 2021-02-25 | Universität Basel | Cell therapy methods |
| CN112402612B (zh) * | 2019-08-21 | 2023-05-26 | 苏州蓝马医疗技术有限公司 | 一种提高肿瘤新抗原疫苗免疫治疗疗效的方法 |
| WO2021062313A1 (en) * | 2019-09-26 | 2021-04-01 | Board Of Regents, The University Of Texas System | Immunogenic egfr peptide compositions and their use in the treatment of cancer |
| WO2021092331A1 (en) * | 2019-11-06 | 2021-05-14 | Ohio State Innovation Foundation | Targeting circular pcmtd1 in leukemias with p53 mutations and/or bcr/abl fusions |
| EP4056197A4 (en) * | 2019-11-07 | 2023-09-06 | Shenzhen Gino Biotechnology Co., Ltd. | TUMOR-SPECIFIC POLYPEPTIDE SEQUENCE AND USE THEREOF |
| AU2020384374A1 (en) * | 2019-11-15 | 2022-06-09 | Seattle Project Corp. | Antigen-binding proteins targeting shared neoantigens |
| CN114729403A (zh) * | 2019-11-22 | 2022-07-08 | 新加坡国立大学 | 用于鉴定和验证共有候选抗原和共有抗原特异性t淋巴细胞对的方法和系统 |
| CA3165862A1 (en) | 2019-12-23 | 2021-07-01 | The Regents Of The University Of California | Stabilization of mhc complexes |
| CN113117081B (zh) * | 2019-12-30 | 2024-12-24 | 上海海洋大学 | ZC3H12b基因或蛋白的用途及一种肝脏疾病动物模型的建立方法 |
| WO2021138447A1 (en) | 2019-12-31 | 2021-07-08 | Elixirgen Therapeutics, Inc. | Temperature-based transient delivery of nucleic acids and proteins to cells and tissues |
| CN111116728B (zh) * | 2020-01-13 | 2021-04-27 | 郑州大学 | 肿瘤特异性抗原ctl表位肽及其应用 |
| WO2021147954A1 (zh) * | 2020-01-21 | 2021-07-29 | 上海柏全生物科技有限公司 | Semg2抗体及其用途 |
| EP4107176A4 (en) * | 2020-02-20 | 2024-03-20 | Gritstone bio, Inc. | ANTIGEN-BINDING PROTEINS TARGETING THE SHARED ANTIGEN KKLC-1 |
| CN111303268B (zh) * | 2020-03-10 | 2021-08-27 | 江苏兰恩生物治疗技术研究院有限公司 | 子宫肌瘤新抗原、其应用和子宫肌瘤疫苗 |
| CA3171370A1 (en) * | 2020-03-16 | 2021-09-23 | Ugur Sahin | Antigen-specific t cell receptors and t cell epitopes |
| CN113461798A (zh) * | 2020-03-18 | 2021-10-01 | 北京鼎成肽源生物技术有限公司 | 一种输卵管癌靶标抗原、输卵管癌靶标抗原刺激培养的ctl细胞及其应用 |
| WO2021228999A1 (en) * | 2020-05-12 | 2021-11-18 | Institut Curie | Neoantigenic epitopes associated with sf3b1 mutations |
| GB202008688D0 (en) * | 2020-06-09 | 2020-07-22 | Cancer Research Tech Ltd | Chimeric antigen receptor cell |
| CN113817740B (zh) * | 2020-06-19 | 2024-07-09 | 中国科学院化学研究所 | 一种核酸适配体识别并结合ptprf及其相关功能的应用研究 |
| CN111718405B (zh) * | 2020-06-30 | 2022-09-13 | 青岛海兰深生物科技有限公司 | 一种检测抗胰腺癌天然抗体的组合物、试剂盒和方法 |
| US20240279740A1 (en) * | 2020-07-02 | 2024-08-22 | The Johns Hopkins University | Methylated markers for accurate detection of primary central nervous system and systemic diffuse large b cell lymphoma |
| US12295997B2 (en) | 2020-07-06 | 2025-05-13 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| KR20230046313A (ko) | 2020-08-06 | 2023-04-05 | 그릿스톤 바이오, 인코포레이티드 | 다중에피토프 백신 카세트 |
| TW202231292A (zh) | 2020-10-13 | 2022-08-16 | 美商健生生物科技公司 | 用於調節分化簇ｉｖ及／或ｖｉｉｉ的經生物工程改造之ｔ細胞介導之免疫力、材料、及其他方法 |
| US12440537B1 (en) * | 2020-10-13 | 2025-10-14 | Washington University | Compositions and methods for treating skin diseases, disorders, or conditions |
| US11421015B2 (en) | 2020-12-07 | 2022-08-23 | Think Therapeutics, Inc. | Method of compact peptide vaccines using residue optimization |
| US11058751B1 (en) | 2020-11-20 | 2021-07-13 | Think Therapeutics, Inc. | Compositions for optimized RAS peptide vaccines |
| CN116710115A (zh) | 2020-11-20 | 2023-09-05 | 思维疗法股份有限公司 | 用于优化的肽疫苗的组合物和方法 |
| AU2021381384A1 (en) * | 2020-11-20 | 2023-06-22 | Think Therapeutics, Inc. | Compositions and methods for optimized peptide vaccines |
| US12275766B2 (en) * | 2020-12-23 | 2025-04-15 | Janssen Biotech, Inc. | Neoantigen peptide mimics |
| CN112666358A (zh) * | 2021-01-14 | 2021-04-16 | 深圳裕康医学检验实验室 | 一种使用外周血检测抗原免疫原性的方法 |
| CN113150140B (zh) * | 2021-01-25 | 2022-11-04 | 山西农业大学 | 一种sox6二价纳米抗体及其应用 |
| WO2022179568A1 (en) * | 2021-02-25 | 2022-09-01 | Westlake Therapeutics (Hangzhou) Co., Limited | Neoantigenic peptide and its use for treating braf gene mutation related diseases |
| CN117062832A (zh) * | 2021-03-16 | 2023-11-14 | 上海柏全生物科技有限公司 | 精液凝固蛋白的中和抗体及其表位和应用 |
| CN114230655B (zh) * | 2021-03-24 | 2025-02-25 | 深圳市新靶向生物科技有限公司 | 一种与食道癌驱动基因突变相关的抗原肽组合及其应用 |
| CN113861283B (zh) * | 2021-03-24 | 2024-12-06 | 深圳市新靶向生物科技有限公司 | 一种与肺癌驱动基因突变相关的抗原肽及其应用 |
| CN114163513B (zh) * | 2021-03-24 | 2025-02-25 | 深圳市新靶向生物科技有限公司 | 一种与肝癌驱动基因突变相关的抗原肽组合及其应用 |
| US20240218019A1 (en) * | 2021-04-06 | 2024-07-04 | Board Of Regents, The University Of Texas System | Methods and compositions comprising mhc class i peptides |
| US11464842B1 (en) | 2021-04-28 | 2022-10-11 | Think Therapeutics, Inc. | Compositions and method for optimized peptide vaccines using residue optimization |
| IL282814A (en) * | 2021-04-29 | 2022-11-01 | Yeda Res & Dev | T cell receptors directed against ras-derived recurrent neoantigens |
| EP4330380A1 (en) | 2021-04-30 | 2024-03-06 | Tigen Pharma SA | Single vessel expansion of lymphocytes |
| CN113527464B (zh) * | 2021-07-19 | 2024-10-18 | 新景智源生物科技(苏州)有限公司 | 识别mboat2的tcr |
| CN119241504A (zh) | 2021-08-26 | 2025-01-03 | 沃拉斯查疗法公司 | Kif18a的螺吲哚啉抑制剂 |
| CN113721030B (zh) * | 2021-08-30 | 2024-02-13 | 河南中医药大学 | 用于桥本甲状腺炎不同证候特征性自身抗体检测的生物标志物及其应用 |
| CN114085282A (zh) * | 2021-10-15 | 2022-02-25 | 北京臻知医学科技有限责任公司 | 一种肿瘤新生抗原表位肽Pep6及其多聚体和应用 |
| CN114085281A (zh) * | 2021-10-15 | 2022-02-25 | 北京臻知医学科技有限责任公司 | 一种肿瘤抗原表位肽及其多聚体和应用 |
| JP2024541968A (ja) * | 2021-10-28 | 2024-11-13 | ジェネンテック， インコーポレイテッド | 治療的介入のためにｍｈｃ関連抗原を同定するためのシステムおよび方法 |
| WO2023081655A1 (en) * | 2021-11-02 | 2023-05-11 | Fred Hutchinson Cancer Center | T cell immunotherapy for hematologic malignancies having an sf3b1 mutation |
| KR102818249B1 (ko) | 2021-11-11 | 2025-06-10 | 의료법인 명지의료재단 | Kras 특이적 활성화 t 세포 유도용 항원 조성물을 이용한 항원 특이적 t 세포 유도방법 |
| KR102753583B1 (ko) | 2021-11-11 | 2025-01-10 | 의료법인 명지의료재단 | Kras 특이적 활성화 t 세포 유도용 항원 조성물 |
| CN114177274A (zh) * | 2021-12-13 | 2022-03-15 | 中国医学科学院微循环研究所 | Tdrd10蛋白及其编码基因在制备肿瘤治疗药物中的应用、及肿瘤治疗药物 |
| EP4448583A4 (en) * | 2021-12-16 | 2025-12-17 | Univ Johns Hopkins | MANABODIES AGAINST P53 TUMORANTIGENS AND METHOD FOR USE |
| KR102732910B1 (ko) | 2021-12-29 | 2024-11-20 | 의료법인 명지의료재단 | K-ras 특이적 활성화 T 세포를 포함하는 대장암의 예방 및 치료용 약제학적 조성물 및 이의 제조방법 |
| KR102732911B1 (ko) | 2021-12-29 | 2024-11-20 | 의료법인 명지의료재단 | K-ras 특이적 활성화 T 세포를 포함하는 유방암의 예방 및 치료용 약제학적 조성물 및 이의 제조방법 |
| KR102732912B1 (ko) | 2021-12-29 | 2024-11-20 | 의료법인 명지의료재단 | K-ras 특이적 활성화 T 세포를 포함하는 폐 선암종의 예방 및 치료용 약제학적 조성물 및 이의 제조방법 |
| KR102732913B1 (ko) | 2021-12-29 | 2024-11-20 | 의료법인 명지의료재단 | K-ras 특이적 활성화 T 세포를 포함하는 흑색종의 예방 및 치료용 약제학적 조성물 및 이의 제조방법 |
| KR102732909B1 (ko) | 2021-12-29 | 2024-11-20 | 의료법인 명지의료재단 | K-ras 특이적 활성화 T 세포를 포함하는 폐 유두상 선암종의 예방 및 치료용 약제학적 조성물 및 이의 제조방법 |
| TW202340474A (zh) * | 2022-01-11 | 2023-10-16 | 大陸商深圳市珈鈺生物科技有限公司 | 樹突細胞腫瘤疫苗和其用途 |
| US20250179124A1 (en) * | 2022-02-07 | 2025-06-05 | Ubiquitx | Beta-catenin protein degradation |
| CN114524872A (zh) * | 2022-03-09 | 2022-05-24 | 广州诺诚生物技术研发有限公司 | 一种用于乳腺癌检测的单克隆抗体及其试剂盒 |
| KR102772405B1 (ko) * | 2022-06-10 | 2025-02-26 | (주)케어젠 | 근육 손실 저해 및 근육량 증진 활성을 갖는 펩타이드 및 이의 용도 |
| US20250368686A1 (en) * | 2022-06-15 | 2025-12-04 | Okinawa Institute Of Science And Technology School Corporation | Peptide drugs for suppressing tolerance development by blocking homo- and hetero-dimerization of opioid receptors |
| CN115327125A (zh) * | 2022-07-14 | 2022-11-11 | 宁波大学 | 一种蛋白质inf2在制备肝癌诊断标志物中的应用 |
| CN117586344B (zh) * | 2022-08-12 | 2025-07-25 | 上海交通大学医学院附属瑞金医院 | 靶向flt3-d835突变的抗原肽及其在肿瘤免疫治疗中的应用 |
| WO2024077256A1 (en) | 2022-10-07 | 2024-04-11 | The General Hospital Corporation | Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins |
| CN115651984B (zh) * | 2022-10-20 | 2023-04-14 | 山东大学 | 一种生物标志物在评价肿瘤紫杉类化疗耐药性的应用 |
| JP2025541604A (ja) | 2022-11-02 | 2025-12-22 | ティゲン・ファーマ・ソシエテ・アノニム | リンパ球の拡大 |
| EP4368189A1 (en) * | 2022-11-09 | 2024-05-15 | Eberhard Karls Universität Tübingen, Medizinische Fakultät | Peptides and combinations of peptides for use in immunotherapy against acute myeloid leukemia (aml) and other hematological neoplasms |
| CN116024217A (zh) * | 2023-01-16 | 2023-04-28 | 陕西师范大学 | Mff作为靶点在制备治疗卵巢癌和/或评估患卵巢癌风险产品中的应用 |
| US12531162B1 (en) * | 2023-05-31 | 2026-01-20 | Northeastern University | Multi-dimensional phenotypic space for genotype to phenotype mapping and intelligent design of cancer drug therapies using a deep learning net |
| WO2024261339A1 (en) | 2023-06-23 | 2024-12-26 | Tigen Pharma Sa | Lymphocyte-stimulatory matrix (lsm) and uses thereof for expansion of lymphocyte populations |
| CN116948004B (zh) * | 2023-09-13 | 2023-11-21 | 成都朗谷生物科技股份有限公司 | 针对ctnnb1基因h36p突变的肿瘤新抗原多肽及其应用 |
| WO2025064339A1 (en) * | 2023-09-18 | 2025-03-27 | Think Therapeutics, Inc. | Compositions and methods for optimized peptide vaccines |
| US12562256B2 (en) * | 2023-11-07 | 2026-02-24 | New York University | Systems, methods and computer-accessible medium for identifying target pairs for CAR-T therapy |
| CN117567591B (zh) * | 2024-01-11 | 2024-04-26 | 中国人民解放军总医院 | 一种用于研究Tmem247蛋白的新型鼠源Tmem247抗体制备方法和应用 |
| TW202539700A (zh) * | 2024-01-16 | 2025-10-16 | 美商建南德克公司 | 用ｐｄ－１軸結合拮抗劑及ｒｎａ疫苗治療泌尿上皮癌之方法 |
| LU103243B1 (en) | 2024-02-09 | 2025-08-11 | PMCR GmbH | Click chemistry hla tumor antigen polypeptides and pharmaceutical composition comprising the same |
| WO2025168848A1 (en) | 2024-02-09 | 2025-08-14 | IMMUNEO Therapeutics GmbH | Hla tumor antigen polypeptides with delivering aiding capping peptides and pharmaceutical composition comprising the same |
| CN118085058B (zh) * | 2024-02-29 | 2024-08-30 | 漯河医学高等专科学校 | Obscn新抗原表位肽及其应用 |
| CN118326008A (zh) * | 2024-04-18 | 2024-07-12 | 香港大学深圳医院 | 一种基于panel基因测序数据的肿瘤新抗原、筛选方法及应用 |
| CN118955677B (zh) * | 2024-05-29 | 2025-07-22 | 北京艺升控股有限公司 | 一种抗原肽及其应用 |
| CN118930636A (zh) * | 2024-07-17 | 2024-11-12 | 中国科学院微生物研究所 | 一种急性髓系白血病表位肽dnmt3a-r882s的t细胞受体及其应用 |
| CN119320833B (zh) * | 2024-12-18 | 2025-07-11 | 南京农业大学 | 一种与鸡双黄蛋性状相关的ston1基因分子标记引物及其应用 |
| CN121059808B (zh) * | 2025-11-05 | 2026-01-30 | 哈尔滨医科大学 | Pwwp2b作为靶点在制备白血病治疗药物中的应用 |
Family Cites Families (279)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
| US3870790A (en) | 1970-01-22 | 1975-03-11 | Forest Laboratories | Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose |
| US4210644A (en) | 1978-02-23 | 1980-07-01 | The Johns Hopkins University | Male contraception |
| US4226859A (en) | 1979-06-07 | 1980-10-07 | Velsicol Chemical Corporation | Pyridyl esters of N-alkylidene-substituted phosphor- and phosphonamidic acids |
| US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
| US4379454A (en) | 1981-02-17 | 1983-04-12 | Alza Corporation | Dosage for coadministering drug and percutaneous absorption enhancer |
| ZA825384B (en) | 1981-07-31 | 1983-05-25 | Tillott J B Ltd | Orally administrable pharmaceutical compositions |
| US4369172A (en) | 1981-12-18 | 1983-01-18 | Forest Laboratories Inc. | Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose |
| US7767449B1 (en) | 1981-12-24 | 2010-08-03 | Health Research Incorporated | Methods using modified vaccinia virus |
| US5174993A (en) | 1981-12-24 | 1992-12-29 | Health Research Inc. | Recombinant avipox virus and immunological use thereof |
| US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
| US5364773A (en) | 1991-03-07 | 1994-11-15 | Virogenetics Corporation | Genetically engineered vaccine strain |
| US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
| US5110587A (en) | 1981-12-24 | 1992-05-05 | Health Research, Incorporated | Immunogenic composition comprising synthetically modified vaccinia virus |
| US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
| US5833975A (en) | 1989-03-08 | 1998-11-10 | Virogenetics Corporation | Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence |
| US4588585A (en) | 1982-10-19 | 1986-05-13 | Cetus Corporation | Human recombinant cysteine depleted interferon-β muteins |
| US7045313B1 (en) | 1982-11-30 | 2006-05-16 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA |
| US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
| GB8311018D0 (en) | 1983-04-22 | 1983-05-25 | Amersham Int Plc | Detecting mutations in dna |
| DE3583799D1 (de) | 1985-01-11 | 1991-09-19 | Abbott Lab Ltd | Feste zubereitung mit langsamer freisetzung. |
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| US4743249A (en) | 1986-02-14 | 1988-05-10 | Ciba-Geigy Corp. | Dermal and transdermal patches having a discontinuous pattern adhesive layer |
| US4844893A (en) | 1986-10-07 | 1989-07-04 | Scripps Clinic And Research Foundation | EX vivo effector cell activation for target cell killing |
| US4906169A (en) | 1986-12-29 | 1990-03-06 | Rutgers, The State University Of New Jersey | Transdermal estrogen/progestin dosage unit, system and process |
| US5023084A (en) | 1986-12-29 | 1991-06-11 | Rutgers, The State University Of New Jersey | Transdermal estrogen/progestin dosage unit, system and process |
| US4816540A (en) | 1987-06-12 | 1989-03-28 | Yasuhiko Onishi | Cationic graft-copolymer |
| US5422119A (en) | 1987-09-24 | 1995-06-06 | Jencap Research Ltd. | Transdermal hormone replacement therapy |
| US5035891A (en) | 1987-10-05 | 1991-07-30 | Syntex (U.S.A.) Inc. | Controlled release subcutaneous implant |
| CA1341245C (en) | 1988-01-12 | 2001-06-05 | F. Hoffmann-La Roche Ag | Recombinant vaccinia virus mva |
| US5906936A (en) | 1988-05-04 | 1999-05-25 | Yeda Research And Development Co. Ltd. | Endowing lymphocytes with antibody specificity |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| CA2005291C (en) | 1988-12-30 | 1999-01-26 | Beverly Dale | Feline infectious peritonitis virus diagnostic tools |
| US6780407B1 (en) | 1989-03-08 | 2004-08-24 | Aventis Pasteur | Pox virus comprising DNA sequences encoding CEA and B7 antigen |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US4973468A (en) | 1989-03-22 | 1990-11-27 | Cygnus Research Corporation | Skin permeation enhancer compositions |
| US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
| FR2650840B1 (fr) | 1989-08-11 | 1991-11-29 | Bertin & Cie | Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications |
| ATE157012T1 (de) | 1989-11-03 | 1997-09-15 | Univ Vanderbilt | Verfahren zur in vivo-verabreichung von funktionsfähigen fremden genen |
| US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
| US5204253A (en) | 1990-05-29 | 1993-04-20 | E. I. Du Pont De Nemours And Company | Method and apparatus for introducing biological substances into living cells |
| JP2773959B2 (ja) | 1990-07-10 | 1998-07-09 | 信越化学工業株式会社 | 大腸内放出性固形製剤 |
| US5198223A (en) | 1990-10-29 | 1993-03-30 | Alza Corporation | Transdermal formulations, methods and devices |
| US6309647B1 (en) | 1999-07-15 | 2001-10-30 | Aventis Pasteur | Poxvirus—canine dispemper virus (CDV) or measles virus recombinants and compositions and methods employing the recombinants |
| US5756102A (en) | 1990-11-20 | 1998-05-26 | Virogenetics Corporation | Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants |
| US6277558B1 (en) | 1990-11-30 | 2001-08-21 | Kansas University Medical Center | α-3 chain type IV collagen polynucleotides |
| AU1588092A (en) | 1991-02-22 | 1992-09-15 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Transmission blocking vaccine against malaria |
| US6004744A (en) | 1991-03-05 | 1999-12-21 | Molecular Tool, Inc. | Method for determining nucleotide identity through extension of immobilized primer |
| US6004811A (en) | 1991-03-07 | 1999-12-21 | The Massachussetts General Hospital | Redirection of cellular immunity by protein tyrosine kinase chimeras |
| US5766597A (en) | 1991-03-07 | 1998-06-16 | Virogenetics Corporation | Malaria recombinant poxviruses |
| US5843728A (en) | 1991-03-07 | 1998-12-01 | The General Hospital Corporation | Redirection of cellular immunity by receptor chimeras |
| US6753162B1 (en) | 1991-03-07 | 2004-06-22 | The General Hospital Corporation | Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells |
| US5912170A (en) | 1991-03-07 | 1999-06-15 | The General Hospital Corporation | Redirection of cellular immunity by protein-tyrosine kinase chimeras |
| DE69233158T2 (de) | 1991-03-07 | 2004-05-13 | Connaught Technology Corp., Greenville | Gentechnologisch hergestellter stamm für impfstoffe |
| NZ241855A (en) | 1991-03-07 | 1994-04-27 | Gen Hospital Corp | Use of therapeutic cells to obtain cellular response to infection, tumours or autoimmune-generated cells, cells with chimaeric receptors (with binding component and destruction signal), dna encoding the receptor, vectors and antibodies to receptor |
| US5851828A (en) | 1991-03-07 | 1998-12-22 | The General Hospital Corporation | Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells |
| US5756101A (en) | 1991-07-01 | 1998-05-26 | Pasteur Merieux Serums Et Vaccins | Malaria recombinant poxvirus |
| US5407686A (en) | 1991-11-27 | 1995-04-18 | Sidmak Laboratories, Inc. | Sustained release composition for oral administration of active ingredient |
| US8211422B2 (en) | 1992-03-18 | 2012-07-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric receptor genes and cells transformed therewith |
| IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
| EP0646178A1 (en) | 1992-06-04 | 1995-04-05 | The Regents Of The University Of California | expression cassette with regularoty regions functional in the mammmlian host |
| WO2001000225A1 (en) | 1999-06-29 | 2001-01-04 | Epimmune Inc. | Hla binding peptides and their uses |
| US9340577B2 (en) | 1992-08-07 | 2016-05-17 | Epimmune Inc. | HLA binding motifs and peptides and their uses |
| US6991797B2 (en) | 1993-07-02 | 2006-01-31 | Statens Serum Institut | M. tuberculosis antigens |
| AU694519B2 (en) | 1994-04-29 | 1998-07-23 | Immuno Aktiengesellschaft | Recombinant poxviruses with foreign polynucleotides in essential regions |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| US5658785A (en) | 1994-06-06 | 1997-08-19 | Children's Hospital, Inc. | Adeno-associated virus materials and methods |
| US6924128B2 (en) | 1994-12-06 | 2005-08-02 | Targeted Genetics Corporation | Packaging cell lines for generation of high titers of recombinant AAV vectors |
| US6071890A (en) | 1994-12-09 | 2000-06-06 | Genzyme Corporation | Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy |
| US5712149A (en) | 1995-02-03 | 1998-01-27 | Cell Genesys, Inc. | Chimeric receptor molecules for delivery of co-stimulatory signals |
| US5820869A (en) | 1995-06-07 | 1998-10-13 | American Home Products Corporation | Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection |
| US5849303A (en) | 1995-06-07 | 1998-12-15 | American Home Products Corporation | Recombinant feline Immunodeficiency virus subunit vaccines employing baculoviral-expressed envelope glycoproteins derived from isolate NCSU-1 and their use against feline immunodeficiency virus infection |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
| US5705190A (en) | 1995-12-19 | 1998-01-06 | Abbott Laboratories | Controlled release formulation for poorly soluble basic drugs |
| US5849589A (en) | 1996-03-11 | 1998-12-15 | Duke University | Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells |
| FR2750865B1 (fr) | 1996-06-27 | 1998-12-04 | Rhone Merieux | Vaccin vivant recombinant a base d'herpesvirus canin, notamment contre la maladie de carre, la rage ou le virus parainfluenza de type 2 |
| US6090393A (en) | 1996-07-03 | 2000-07-18 | Merial | Recombinant canine adenoviruses, method for making and uses thereof |
| US6156567A (en) | 1996-07-03 | 2000-12-05 | Merial | Truncated transcriptionally active cytomegalovirus promoters |
| FR2751227B1 (fr) | 1996-07-19 | 1998-11-27 | Rhone Merieux | Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives |
| PL332875A1 (en) | 1996-10-17 | 1999-10-25 | Oxford Biomedica Ltd | Retroviral vectors |
| US7198784B2 (en) | 1996-10-17 | 2007-04-03 | Oxford Biomedica (Uk) Limited | Retroviral vectors |
| US7255862B1 (en) | 1996-11-14 | 2007-08-14 | Connaught Technology Corporation | ALVAC/FIV constructs |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| US6489458B2 (en) | 1997-03-11 | 2002-12-03 | Regents Of The University Of Minnesota | DNA-based transposon system for the introduction of nucleic acid into DNA of a cell |
| US6004777A (en) | 1997-03-12 | 1999-12-21 | Virogenetics Corporation | Vectors having enhanced expression, and methods of making and uses thereof |
| US5990091A (en) | 1997-03-12 | 1999-11-23 | Virogenetics Corporation | Vectors having enhanced expression, and methods of making and uses thereof |
| CA2304168A1 (en) | 1997-09-19 | 1999-04-01 | The Trustees Of The University Of Pennsylvania | Methods and cell line useful for production of recombinant adeno-associated viruses |
| CA2303768C (en) | 1997-09-19 | 2009-11-24 | The Trustees Of The University Of Pennsylvania | Methods and vector constructs useful for production of recombinant aav |
| GB9720465D0 (en) | 1997-09-25 | 1997-11-26 | Oxford Biomedica Ltd | Dual-virus vectors |
| US6346415B1 (en) | 1997-10-21 | 2002-02-12 | Targeted Genetics Corporation | Transcriptionally-activated AAV inverted terminal repeats (ITRS) for use with recombinant AAV vectors |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| FR2775601B1 (fr) | 1998-03-03 | 2001-09-21 | Merial Sas | Vaccins vivants recombines et adjuves |
| US6953690B1 (en) | 1998-03-20 | 2005-10-11 | The Trustees Of The University Of Pennsylvania | Compositions and methods for helper-free production of recombinant adeno-associated viruses |
| US6413776B1 (en) | 1998-06-12 | 2002-07-02 | Galapagos Geonomics N.V. | High throughput screening of gene function using adenoviral libraries for functional genomics applications |
| UA73092C2 (uk) | 1998-07-17 | 2005-06-15 | Брістол-Майерс Сквібб Компані | Таблетка з ентеросолюбільним покриттям і спосіб її приготування |
| DE69924735T2 (de) | 1998-07-28 | 2006-01-19 | Tanabe Seiyaku Co., Ltd. | Zur wirkstoffabgabe an zielorten im darm fähige zubereitung |
| KR20010083890A (ko) | 1998-10-05 | 2001-09-03 | 에드워드 에이. 맥더모트, 주니어 | 암 관련 항원 및 그의 용도 |
| ES2340230T3 (es) | 1998-11-10 | 2010-05-31 | University Of North Carolina At Chapel Hill | Vectores viricos y sus procedimientos de preparacion y administracion. |
| US7160682B2 (en) | 1998-11-13 | 2007-01-09 | Regents Of The University Of Minnesota | Nucleic acid transfer vector for the introduction of nucleic acid into the DNA of a cell |
| US6258595B1 (en) | 1999-03-18 | 2001-07-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods for helper-free production of recombinant adeno-associated viruses |
| US6893865B1 (en) | 1999-04-28 | 2005-05-17 | Targeted Genetics Corporation | Methods, compositions, and cells for encapsidating recombinant vectors in AAV particles |
| NO309798B1 (no) | 1999-04-30 | 2001-04-02 | Targovax As | Peptidblanding, samt farmasoytisk sammensetning og kreftvaksine som innbefatter peptidblandingen |
| US6913922B1 (en) | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
| US6492169B1 (en) | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
| US6793926B1 (en) | 1999-05-27 | 2004-09-21 | Genovo, Inc. | Methods for production of a recombinant adeno-associated virus |
| DE60040147D1 (de) | 1999-05-28 | 2008-10-16 | Targeted Genetics Corp | Methoden und zusammensetzungen zur reduktion des tumor-nekrosis-faktor-spiegels (tnf) bei tnf-assoziierten erkrankungen |
| US6955808B2 (en) | 1999-09-24 | 2005-10-18 | Uab Research Foundation | Capsid-modified recombinant adenovirus and methods of use |
| US7115391B1 (en) | 1999-10-01 | 2006-10-03 | Genovo, Inc. | Production of recombinant AAV using adenovirus comprising AAV rep/cap genes |
| CA2397998A1 (en) | 2000-01-28 | 2001-08-02 | Statens Serum Institut | Hiv peptides and nucleic acids encoding them for diagnosis and control of hiv infection |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| CA2406864A1 (en) | 2000-02-24 | 2001-08-30 | Life Technologies Corporation | Simultaneous stimulation and concentration of cells |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| CN1291012C (zh) | 2000-03-14 | 2006-12-20 | 巴法里安诺迪克有限公司 | 修饰的安卡拉牛痘病毒(mva)的变株 |
| US6686184B1 (en) | 2000-05-25 | 2004-02-03 | President And Fellows Of Harvard College | Patterning of surfaces utilizing microfluidic stamps including three-dimensionally arrayed channel networks |
| GB0024550D0 (https=) | 2000-10-06 | 2000-11-22 | Oxford Biomedica Ltd | |
| US7628980B2 (en) | 2000-11-23 | 2009-12-08 | Bavarian Nordic A/S | Modified vaccinia virus ankara for the vaccination of neonates |
| PL212047B1 (pl) | 2000-11-23 | 2012-08-31 | Bavarian Nordic As | Zmodyfikowany wirus krowianki szczepu Ankara MVA-BN i jego pochodna, genom i zawierające je kompozycja farmaceutyczna, zwłaszcza szczepionka oraz ich zastosowania |
| US7097842B2 (en) | 2000-11-23 | 2006-08-29 | Bavarian Nordic A/S | Modified vaccinia virus ankara for the vaccination of neonates |
| US7445924B2 (en) | 2000-11-23 | 2008-11-04 | Bavarian Nordic A/S | Modified Vaccinia Ankara virus variant and cultivation method |
| US6923973B1 (en) | 2001-02-22 | 2005-08-02 | Board Of Regents, The University Of Texas System | Peptide and DNA immunization against Coccidioides immitis infections |
| US20030104008A1 (en) | 2001-04-06 | 2003-06-05 | Loosmore Sheena May | Recombinant vaccine against west nile virus |
| WO2003004989A2 (en) * | 2001-06-21 | 2003-01-16 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer |
| AU2002321581C1 (en) | 2001-08-31 | 2008-09-18 | Adaptimmune Limited | Soluble T cell receptor |
| ES2537074T3 (es) | 2001-09-06 | 2015-06-02 | Agensys, Inc. | Ácido nucleico y proteína correspondiente denominados STEAP-1 útiles en el tratamiento y la detección de cáncer |
| US20040142325A1 (en) * | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| WO2003057171A2 (en) | 2002-01-03 | 2003-07-17 | The Trustees Of The University Of Pennsylvania | Activation and expansion of t-cells using an engineered multivalent signaling platform |
| BR0309254A (pt) | 2002-04-12 | 2005-03-01 | Medarex Inc | Uso de um anticorpo anti-ctla-4 |
| NZ536592A (en) | 2002-04-19 | 2007-01-26 | Bavarian Nordic As | Modified vaccinia virus ankara for the vaccination of neonates |
| AU2003231048A1 (en) | 2002-04-22 | 2003-11-03 | Regents Of The University Of Minnesota | Transposon system and methods of use |
| US7501127B2 (en) | 2002-05-16 | 2009-03-10 | Bavarian Nordic A/S | Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara |
| US20040053304A1 (en) | 2002-06-05 | 2004-03-18 | Case Western Reserve University | Methods and compositions for detecting cancers |
| EP1512014B1 (en) | 2002-06-13 | 2009-08-05 | MERCK PATENT GmbH | Methods for the identification of all-antigens and their use for cancer therapy and transplantation |
| JP2006507921A (ja) | 2002-06-28 | 2006-03-09 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | 流体分散のための方法および装置 |
| GB0220467D0 (en) | 2002-09-03 | 2002-10-09 | Oxford Biomedica Ltd | Composition |
| AU2003265948B8 (en) | 2002-09-06 | 2009-09-03 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy |
| ATE442378T1 (de) | 2002-09-20 | 2009-09-15 | Int Inst Cancer Immunology Inc | Substituierte wt1-peptide |
| US20070224201A1 (en) * | 2002-10-02 | 2007-09-27 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| AU2003271904B2 (en) | 2002-10-09 | 2009-03-05 | Adaptimmune Limited | Single chain recombinant T cell receptors |
| DE60327795D1 (de) | 2002-11-09 | 2009-07-09 | Immunocore Ltd | T zell rezeptor "display" |
| CA2511625A1 (en) | 2002-12-23 | 2004-07-15 | City Of Hope | Modified vaccinia ankara expressing p53 in cancer immunotherapy |
| GB0304068D0 (en) | 2003-02-22 | 2003-03-26 | Avidex Ltd | Substances |
| US20060078893A1 (en) | 2004-10-12 | 2006-04-13 | Medical Research Council | Compartmentalised combinatorial chemistry by microfluidic control |
| US20040197312A1 (en) | 2003-04-02 | 2004-10-07 | Marina Moskalenko | Cytokine-expressing cellular vaccine combinations |
| EP2127736A1 (en) | 2003-04-10 | 2009-12-02 | The President and Fellows of Harvard College | Formation and control of fluidic species |
| ES2456666T3 (es) | 2003-04-18 | 2014-04-23 | Biotech Synergy, Inc. | Péptidos antígenos HLA-A2 asociados a un tumor y composiciones |
| US7985739B2 (en) | 2003-06-04 | 2011-07-26 | The Board Of Trustees Of The Leland Stanford Junior University | Enhanced sleeping beauty transposon system and methods for using the same |
| SI1651265T1 (sl) | 2003-07-24 | 2008-10-31 | Merial Ltd | Formulacije cepiva, ki obsegajo emulzijo olje v vodi |
| CN104069784B (zh) | 2003-08-27 | 2017-01-11 | 哈佛大学 | 流体物种的电子控制 |
| US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
| US7084247B2 (en) | 2004-03-11 | 2006-08-01 | Peptimmune, Inc. | Identification of self and non-self antigens implicated in autoimmune diseases |
| TWI417303B (zh) | 2004-03-11 | 2013-12-01 | Fresenius Kabi De Gmbh | 經由還原胺化作用製得之羥烷基澱粉及蛋白質的接合物 |
| US20050221339A1 (en) | 2004-03-31 | 2005-10-06 | Medical Research Council Harvard University | Compartmentalised screening by microfluidic control |
| NZ550815A (en) | 2004-05-19 | 2009-04-30 | Immunocore Ltd | Method of improving T cell receptors |
| DK1765860T3 (da) | 2004-05-19 | 2009-03-09 | Immunocore Ltd | Ny-ESO-T.cellereceptor med höj affinitet |
| US20060008468A1 (en) | 2004-06-17 | 2006-01-12 | Chih-Sheng Chiang | Combinations of tumor-associated antigens in diagnostics for various types of cancers |
| US8361794B2 (en) | 2004-06-29 | 2013-01-29 | Immunocore Limited | Cells expressing a modified T cell receptor |
| JP4772045B2 (ja) | 2004-07-16 | 2011-09-14 | アメリカ合衆国 | Ｃｍｖ／ｒ核酸コンストラクトを含むａｉｄｓに対するワクチン |
| US7220549B2 (en) | 2004-12-30 | 2007-05-22 | Helicos Biosciences Corporation | Stabilizing a nucleic acid for nucleic acid sequencing |
| AU2006214278C1 (en) | 2005-02-16 | 2012-07-19 | Miltenyi Biotec Technology, Inc. | Lentiviral vectors and their use |
| US7283337B2 (en) | 2005-03-04 | 2007-10-16 | Headway Technologies, Inc. | Abutted exchange bias design for sensor stabilization |
| EP2248578B1 (en) | 2005-03-04 | 2012-06-06 | President and Fellows of Harvard College | Method for forming multiple emulsions |
| AR052741A1 (es) | 2005-04-08 | 2007-03-28 | Noxxon Pharma Ag | Acidos nucleicos de union a ghrelin |
| RU2494107C2 (ru) | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| WO2006125962A2 (en) | 2005-05-25 | 2006-11-30 | Medigene Limited | T cell receptors which specifically bind to vygfvracl-hla-a24 |
| EP1921089A4 (en) | 2005-08-03 | 2009-05-06 | Medical & Biol Lab Co Ltd | PEPTIDE CYTOTOXIC LYMPHOCYTE T EPOPOPY AND USE THEREOF |
| EP3611266B1 (en) | 2005-08-23 | 2022-11-09 | The Trustees of the University of Pennsylvania | Rna containing modified nucleosides and methods of use thereof |
| US20070112754A1 (en) | 2005-11-15 | 2007-05-17 | Honeywell International Inc. | Method and apparatus for identifying data of interest in a database |
| JP2009536313A (ja) | 2006-01-11 | 2009-10-08 | レインダンス テクノロジーズ， インコーポレイテッド | ナノリアクターの形成および制御において使用するマイクロ流体デバイスおよび方法 |
| WO2007089541A2 (en) | 2006-01-27 | 2007-08-09 | President And Fellows Of Harvard College | Fluidic droplet coalescence |
| US8793895B2 (en) | 2006-02-10 | 2014-08-05 | Praxair Technology, Inc. | Lyophilization system and method |
| CA2651796A1 (en) | 2006-02-27 | 2007-09-07 | Arizona Board Of Regents For And On Behalf Of Arizona State University | Identification and use of novopeptides for the treatment of cancer |
| US7919079B2 (en) | 2006-03-31 | 2011-04-05 | Biosante Pharmaceuticals, Inc. | Cancer immunotherapy compositions and methods of use |
| US9283260B2 (en) | 2006-04-21 | 2016-03-15 | Amgen Inc. | Lyophilized therapeutic peptibody formulations |
| ATE540750T1 (de) | 2006-05-11 | 2012-01-15 | Raindance Technologies Inc | Mikrofluidische vorrichtung und verfahren |
| US8768629B2 (en) | 2009-02-11 | 2014-07-01 | Caris Mpi, Inc. | Molecular profiling of tumors |
| EP2032719A2 (en) | 2006-06-02 | 2009-03-11 | GlaxoSmithKline Biologicals S.A. | Method for identifying whether a patient will be responder or not to immunotherapy |
| US20100035973A1 (en) | 2006-07-17 | 2010-02-11 | Nationwide Children's Hospital, Inc. | Disruption of programmed death 1 (pd-1) ligand to adjuvant adeno-associated virus vector vaccines |
| WO2008039818A2 (en) | 2006-09-26 | 2008-04-03 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Modified t cell receptors and related materials and methods |
| EP2087000A2 (en) | 2006-09-29 | 2009-08-12 | Immunocore Ltd. | T cell therapies |
| US8349167B2 (en) | 2006-12-14 | 2013-01-08 | Life Technologies Corporation | Methods and apparatus for detecting molecular interactions using FET arrays |
| US8262900B2 (en) | 2006-12-14 | 2012-09-11 | Life Technologies Corporation | Methods and apparatus for measuring analytes using large scale FET arrays |
| US9045556B2 (en) | 2007-02-07 | 2015-06-02 | Nec Corporation | Therapeutic agent for cancer |
| US20100099090A1 (en) | 2007-03-05 | 2010-04-22 | Bristol-Mayers Squibb Company | Biomarkers and methods for determining sensitivity to ctla-4 antagonists |
| CA2681567C (en) | 2007-03-22 | 2016-07-19 | The Regents Of The University Of Colorado, A Body Corporate | Method of preparing an immunologically-active adjuvant-bound dried vaccine composition |
| WO2008147186A1 (en) | 2007-05-31 | 2008-12-04 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | P53 peptide vaccine |
| ES2776406T3 (es) | 2007-07-12 | 2020-07-30 | Gitr Inc | Terapias de combinación que emplean moléculas de enlazamiento a GITR |
| US20090028857A1 (en) | 2007-07-23 | 2009-01-29 | Cell Genesys, Inc. | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
| EP2283028A2 (en) | 2007-08-08 | 2011-02-16 | The Board of Regents of The University of Texas System | Vegfr-1/nrp-1 targeting peptides |
| EP2185182A1 (en) | 2007-09-11 | 2010-05-19 | Mondobiotech Laboratories AG | Use of grf-1 (1-29 ) and corticotropin-releasing factor as therapeutic agents |
| AU2008314925B2 (en) | 2007-10-25 | 2013-11-07 | Toray Industries, Inc. | Immune response inducer |
| AU2008345036A1 (en) | 2007-12-28 | 2009-07-09 | John Wayne Cancer Institute | Use of methylation status of MINT loci and tumor-related genes as a marker for melanoma and breast cancer |
| WO2009088786A1 (en) | 2007-12-31 | 2009-07-16 | Nanocor Therapeutics, Inc. | Rna interference for the treatment of heart failure |
| WO2009102909A2 (en) | 2008-02-15 | 2009-08-20 | Board Of Regents, The University Of Texas System | Anti-cancer vaccines |
| EP2274437B1 (en) * | 2008-04-10 | 2015-12-23 | Cell Signaling Technology, Inc. | Compositions and methods for detecting egfr mutations in cancer |
| EP2331680B1 (en) | 2008-09-22 | 2017-05-03 | Baylor College Of Medicine | Methods and compositions for generating an immune response by inducing cd40 and pattern recognition receptor adapters |
| MX2011004050A (es) | 2008-10-17 | 2011-05-10 | Genentech Inc | Metodo de tratamiento. |
| US20100137143A1 (en) | 2008-10-22 | 2010-06-03 | Ion Torrent Systems Incorporated | Methods and apparatus for measuring analytes |
| CN102272153B (zh) | 2008-11-24 | 2015-04-15 | 德国慕尼黑亥姆霍兹研究中心健康和环境有限公司 | 高亲和力t细胞受体及其应用 |
| PT2413956T (pt) | 2009-04-02 | 2016-12-30 | Vaxon Biotech | Identificação, optimização e utilização de epitopos crípticos hla-a24 para imunoterapia |
| CA2776241A1 (en) | 2009-10-30 | 2011-05-05 | Novozymes Biopharma Dk A/S | Albumin variants |
| JP5946770B2 (ja) | 2009-12-10 | 2016-07-06 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | オリゴペプチドを含む医薬組成物 |
| US9023802B2 (en) | 2009-12-14 | 2015-05-05 | Immatics Biotechnologies Gmbh | HLA-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof |
| EP2517025B1 (en) | 2009-12-23 | 2019-11-27 | Bio-Rad Laboratories, Inc. | Methods for reducing the exchange of molecules between droplets |
| GB201006360D0 (en) | 2010-04-16 | 2010-06-02 | Immatics Biotechnologies Gmbh | Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development |
| TW201138782A (en) | 2010-04-26 | 2011-11-16 | Besins Healthcare Lu Sarl | Low-oil pharmaceutical emulsion compositions comprising progestogen |
| BR112012029066A2 (pt) * | 2010-05-14 | 2020-09-01 | The General Hospital Corporation | composições e processos de identificação de neoantígenos específicos de tumor. |
| WO2011146862A1 (en) | 2010-05-21 | 2011-11-24 | Bellicum Pharmaceuticals, Inc. | Methods for inducing selective apoptosis |
| CN102946907A (zh) | 2010-05-28 | 2013-02-27 | 牛津生物医学（英国）有限公司 | 慢病毒载体向脑的递送 |
| WO2011153009A1 (en) | 2010-06-02 | 2011-12-08 | Abraxis Bioscience, Llc | Methods of treating bladder cancer |
| EP2608799B1 (en) | 2010-08-24 | 2018-12-12 | University of Pittsburgh - Of the Commonwealth System of Higher Education | Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| GB2506760B (en) | 2011-01-14 | 2015-07-22 | Genefirst Ltd | Allele specific primers for EGFR exon 21 specific mutations |
| EP2478915A1 (en) | 2011-01-24 | 2012-07-25 | Genticel | CyaA-carried polypeptide(s) and use to induce both therapeutic and prophylactic immune responses |
| EP3859011A1 (en) | 2011-02-11 | 2021-08-04 | Bio-Rad Laboratories, Inc. | Methods for forming mixed droplets |
| WO2012129201A1 (en) | 2011-03-22 | 2012-09-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
| US20130071414A1 (en) | 2011-04-27 | 2013-03-21 | Gianpietro Dotti | Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies |
| US20120295960A1 (en) | 2011-05-20 | 2012-11-22 | Oxford Biomedica (Uk) Ltd. | Treatment regimen for parkinson's disease |
| WO2012159643A1 (en) | 2011-05-24 | 2012-11-29 | Biontech Ag | Individualized vaccines for cancer |
| HRP20211595T1 (hr) | 2011-05-24 | 2022-01-21 | BioNTech SE | Individualizirana cjepiva protiv raka |
| HK1199066A1 (en) | 2011-08-18 | 2015-06-19 | Nestec S.A. | Compositions and methods for detecting allelic variants |
| JP6153526B2 (ja) * | 2011-09-06 | 2017-06-28 | エージェンシー フォー サイエンス，テクノロジー アンド リサーチ | ポリペプチドワクチン |
| ES2834070T3 (es) | 2011-09-15 | 2021-06-16 | Us Health | Receptores de células T que reconocen MAGE restringido por HLA-A1 o HLA-Cw7 |
| EP3692794A1 (en) | 2011-09-16 | 2020-08-12 | Baylor College of Medicine | Targeting the tumor microenvironment using manipulated nkt cells |
| WO2013086464A1 (en) | 2011-12-07 | 2013-06-13 | The Broad Institute, Inc. | Markers associated with chronic lymphocytic leukemia prognosis and progression |
| US20130210014A1 (en) | 2012-02-10 | 2013-08-15 | Jeff Sharman | Method for determining the prognosis and therapeutic response in chronic lymphocytic leukemia (cll) patients |
| US20160130641A1 (en) | 2012-02-15 | 2016-05-12 | Janssen Diagnostics, Llc | Highly sensitive method for detecting low frequency mutations |
| SG11201405578TA (en) | 2012-03-09 | 2014-11-27 | Oncotherapy Science Inc | Pharmaceutical composition containing peptide |
| SG10201609210SA (en) | 2012-05-03 | 2016-12-29 | Hutchinson Fred Cancer Res | Enhanced affinity t cell receptors and methods for making the same |
| AU2013255511B2 (en) | 2012-05-04 | 2016-01-28 | Pfizer Inc. | Prostate-associated antigens and vaccine-based immunotherapy regimens |
| CN113967253A (zh) | 2012-05-15 | 2022-01-25 | 百时美施贵宝公司 | 通过破坏pd-1/pd-l1信号传输的免疫治疗 |
| KR102437522B1 (ko) | 2012-05-25 | 2022-08-26 | 셀렉티스 | 면역요법을 위한 동종이형 및 면역억제제 저항성인 ｔ 세포의 조작 방법 |
| SG11201408128WA (en) | 2012-06-15 | 2015-01-29 | Adaptive Biotechnologies Corp | Uniquely tagged rearranged adaptive immune receptor genes in a complex gene set |
| CA2879024A1 (en) | 2012-07-12 | 2014-01-16 | Persimmune, Inc. | Personalized cancer vaccines and adoptive immune cell therapies |
| WO2014009535A2 (en) | 2012-07-12 | 2014-01-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the survival time and treatment responsiveness of a patient suffering from a solid cancer with a signature of at least 7 genes |
| CN104507537A (zh) | 2012-07-13 | 2015-04-08 | 宾夕法尼亚大学董事会 | 用于调节car t细胞的组合物和方法 |
| AU2013295652B2 (en) | 2012-07-27 | 2018-02-08 | The Board Of Trustees Of The University Of Illinois | Engineering T-cell receptors |
| EP3718556A3 (en) | 2012-08-31 | 2020-12-30 | University Of Virginia Patent Foundation | Target peptides for immunotherapy and diagnostics |
| EP2898096B1 (en) | 2012-09-21 | 2024-02-14 | The Broad Institute, Inc. | Methods for labeling of rnas |
| EP2906684B8 (en) | 2012-10-10 | 2020-09-02 | Sangamo Therapeutics, Inc. | T cell modifying compounds and uses thereof |
| WO2014056986A1 (en) | 2012-10-11 | 2014-04-17 | Universitat De Barcelona | Method to predict the clinical evolution of a patient suffering of chronic lymphocytic leukemia (cll) |
| GB2508414A (en) * | 2012-11-30 | 2014-06-04 | Max Delbrueck Centrum | Tumour specific T cell receptors (TCRs) |
| WO2014085802A1 (en) | 2012-11-30 | 2014-06-05 | The Broad Institute, Inc. | High-throughput dynamic reagent delivery system |
| CN110195097B (zh) | 2013-02-07 | 2025-01-24 | 新泽西鲁特格斯州立大学 | 高度选择性核酸扩增引物 |
| PT2961831T (pt) | 2013-02-26 | 2020-10-12 | Memorial Sloan Kettering Cancer Center | Composições e métodos para imunoterapêutica |
| EP3628322A1 (en) | 2013-03-01 | 2020-04-01 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Cd8+ t cells that also express pd-1 and/or tim-3 for the treatment of cancer |
| RU2671897C2 (ru) | 2013-03-01 | 2018-11-07 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез | Способы получения из опухоли обогащенных популяций реактивных в отношении опухоли т-клеток |
| US10176294B2 (en) | 2013-03-15 | 2019-01-08 | The Broad Institute, Inc. | Accurate typing of HLA through exome sequencing |
| CN118750591A (zh) * | 2013-04-07 | 2024-10-11 | 博德研究所 | 用于个性化瘤形成疫苗的组合物和方法 |
| WO2014172606A1 (en) | 2013-04-19 | 2014-10-23 | The Brigham And Women's Hospital, Inc. | Methods for modulating immune responses during chronic immune conditions by targeting metallothioneins |
| MX2015015638A (es) | 2013-05-13 | 2016-10-28 | Cellectis | Metodos para diseñar celulas t altamente activas para inmunoterapia. |
| WO2014191128A1 (en) | 2013-05-29 | 2014-12-04 | Cellectis | Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system |
| EP3004877A4 (en) | 2013-06-06 | 2017-04-19 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for identification, assessment prevention, and treatment of cancer using pd-l1 isoforms |
| TWI775117B (zh) * | 2013-08-05 | 2022-08-21 | 德商伊瑪提克斯生物科技有限公司 | 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（二） |
| WO2015077717A1 (en) | 2013-11-25 | 2015-05-28 | The Broad Institute Inc. | Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status |
| US20160310584A1 (en) | 2013-12-06 | 2016-10-27 | The Broad Institute Inc. | Formulations for neoplasia vaccines |
| EP3082853A2 (en) | 2013-12-20 | 2016-10-26 | The Broad Institute, Inc. | Combination therapy with neoantigen vaccine |
| DK3152569T3 (da) | 2014-06-05 | 2020-08-17 | Aimm Therapeutics Bv | Midler og fremgangsmåder til bestemmelse af t-cellegenkendelse |
| RS59710B1 (sr) | 2014-08-07 | 2020-01-31 | Pharmassist Ltd | Metod određivanja mutacionog statusa pik3ca u uzorku |
| EP3198031A1 (en) | 2014-09-22 | 2017-08-02 | Dana Farber Cancer Institute, Inc. | Use of clonal evolution analysis for ibrutinib resistance in chronic lymphocytic leukemia patients |
| US10993997B2 (en) | 2014-12-19 | 2021-05-04 | The Broad Institute, Inc. | Methods for profiling the t cell repertoire |
| US10975442B2 (en) | 2014-12-19 | 2021-04-13 | Massachusetts Institute Of Technology | Molecular biomarkers for cancer immunotherapy |
| US20190099475A1 (en) * | 2015-04-08 | 2019-04-04 | Nantomics, Llc | Cancer neoepitopes |
| CA2988388C (en) * | 2015-04-23 | 2022-11-22 | Nantomics, Llc | Cancer neoepitopes |
| WO2016183042A1 (en) | 2015-05-10 | 2016-11-17 | Quandx Inc. | Ultra sensitive probes for detection of nucleic acid |
| TW202523682A (zh) | 2015-05-20 | 2025-06-16 | 美商博德研究所有限公司 | 共有之gata3相關之腫瘤特異性新抗原 |
| TW202241500A (zh) | 2015-06-09 | 2022-11-01 | 美商博德研究所有限公司 | 用於贅瘤疫苗之調配物及其製備方法 |
| FI3436048T3 (fi) * | 2016-03-31 | 2025-09-15 | Biontech Us Inc | Neoantigeeneja ja niiden käyttömenetelmiä |
| EP3446119A1 (en) | 2016-04-18 | 2019-02-27 | The Broad Institute Inc. | Improved hla epitope prediction |
| WO2018140391A1 (en) | 2017-01-24 | 2018-08-02 | The Broad Institute, Inc. | Compositions and methods for detecting a mutant variant of a polynucleotide |
-
2016
- 2016-05-20 TW TW114108178A patent/TW202523682A/zh unknown
- 2016-05-20 CR CR20200476A patent/CR20200476A/es unknown
- 2016-05-20 CN CN202211239802.9A patent/CN116196401A/zh active Pending
- 2016-05-20 CN CN201680042436.4A patent/CN108025048B/zh active Active
- 2016-05-20 JP JP2017560196A patent/JP6913032B2/ja active Active
- 2016-05-20 US US15/575,328 patent/US10835585B2/en active Active
- 2016-05-20 RU RU2017144467A patent/RU2733754C2/ru active
- 2016-05-20 BR BR112017024797-6A patent/BR112017024797A2/pt not_active Application Discontinuation
- 2016-05-20 PE PE2017002446A patent/PE20180670A1/es unknown
- 2016-05-20 AU AU2016264623A patent/AU2016264623B2/en active Active
- 2016-05-20 MX MX2017014700A patent/MX2017014700A/es unknown
- 2016-05-20 WO PCT/US2016/033452 patent/WO2016187508A2/en not_active Ceased
- 2016-05-20 KR KR1020177036611A patent/KR20180010229A/ko not_active Ceased
- 2016-05-20 IL IL255769A patent/IL255769B2/en unknown
- 2016-05-20 IL IL294183A patent/IL294183B2/en unknown
- 2016-05-20 KR KR1020247038026A patent/KR20240166604A/ko active Pending
- 2016-05-20 TW TW112105056A patent/TWI878795B/zh active
- 2016-05-20 CA CA2986235A patent/CA2986235A1/en active Pending
- 2016-05-20 TW TW105115840A patent/TWI806815B/zh active
- 2016-05-20 CR CR20170584A patent/CR20170584A/es unknown
- 2016-05-20 MY MYPI2017001689A patent/MY190974A/en unknown
- 2016-05-20 EP EP16732018.3A patent/EP3297660A2/en active Pending
- 2016-05-20 HK HK18111576.9A patent/HK1252267A1/zh unknown
- 2016-05-20 CR CR20230191A patent/CR20230191A/es unknown
-
2017
- 2017-11-16 MX MX2024006806A patent/MX2024006806A/es unknown
- 2017-11-16 MX MX2023005122A patent/MX2023005122A/es unknown
- 2017-11-20 CL CL2017002945A patent/CL2017002945A1/es unknown
- 2017-12-13 CO CONC2017/0012835A patent/CO2017012835A2/es unknown
- 2017-12-15 PH PH12017502321A patent/PH12017502321A1/en unknown
- 2017-12-20 EC ECIEPI201784137A patent/ECSP17084137A/es unknown
-
2020
- 2020-04-27 US US16/859,252 patent/US20200368337A1/en active Pending
-
2021
- 2021-07-09 JP JP2021114423A patent/JP7282834B2/ja active Active
-
2022
- 2022-09-28 AU AU2022241521A patent/AU2022241521B2/en active Active
-
2023
- 2023-04-13 IL IL302102A patent/IL302102B1/en unknown
- 2023-05-17 JP JP2023081513A patent/JP2023103405A/ja active Pending
- 2023-08-16 CL CL2023002421A patent/CL2023002421A1/es unknown
-
2025
- 2025-06-23 AU AU2025204711A patent/AU2025204711A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112017024797A2 (pt) | neoantígenos partilhados | |
| CY1125508T1 (el) | Υποδοχεις τ-κυτταρων ειδικων για το συμπλοκο καρκινικου αντιγονου ny-eso-1-hla-a 02 | |
| CY1122465T1 (el) | Συνδυασμενη φαρμακευτικη συνθεση | |
| SA519410362B1 (ar) | مستقبل للخلايا التائية (tcr) وببتيدات | |
| CY1119770T1 (el) | Νεο στελεχος bifidobacterium animalis υποειδ. lactis cect 8145 και χρηση αυτου για την αγωγη και/ή την προληψη του υπερβαρους και της παχυσαρκιας και των σχετικων παθησεων | |
| ZA201904725B (en) | Personalised immunogenic peptide identification platform | |
| BR112016009402A2 (pt) | Peptídeo, linfócitos t citotóxicos (ltc) ativados, método para sua produção, anticorpo, receptor de células t, ácido nucleico, célula hospedeira, uso dos mesmos, kit, método para produzir uma vacina anticâncer personalizada para um paciente individual | |
| JOP20190097A1 (ar) | الجلوبولينات المناعية واستخداماتها | |
| BR112018073761A2 (pt) | proteínas de ligação ao cd3 de fragmento variável de cadeia única | |
| EA201791150A1 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии гепатоклеточной карциномы (гкк) и других видов рака | |
| EA201791853A1 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии рака поджелудочной железы и других видов рака | |
| BR112018003460A2 (pt) | peptídeos, combinações de peptídeos e suportes para emprego na imunoterapia de diversos cânceres | |
| EA201890278A1 (ru) | Антитела к pd-l1 | |
| EA201792573A1 (ru) | Триспецифические связанные белки и способы их применения | |
| BR112016006978A2 (pt) | inibidores de tirosina quinase de bruton | |
| MX2019005272A (es) | Peptidos cancerigenos universales derivados de telomerasa. | |
| BR112014021325A2 (pt) | Formulação farmacêutica líquida e formulação liofilizada | |
| BR112017008416A2 (pt) | ?produtos terapêuticos à base de lantionina sintetase c-like 2?. | |
| EA201591579A1 (ru) | Способы лечения болезни крона при помощи анти-il-23 антитела | |
| CY1124667T1 (el) | Τροποποιημενο rna που κωδικοποιει πολυπεπτιδια vegf-a, φαρμακοτεχνικες μορφες, και χρησεις που σχετιζονται με αυτα | |
| BR112016002572A2 (pt) | peptídeos | |
| CY1124846T1 (el) | Καινοτομα πεπτιδια και συνδυασμος πεπτιδιων για χρηση στην ανοσοθεραπεια εναντι του ηπατοκυτταρικου καρκινωματος (hcc) και αλλων καρκινων | |
| EP3811949A4 (en) | COMBINATION DRUG CONTAINING GEMCITABIN-ENCAPSULATED LIPOSOME COMPOSITION AND IMMUNE TEST POINT BLOCKADE | |
| MX2021003660A (es) | Composicion inyectable. | |
| BR112022000778A2 (pt) | Anticorpos anti-grp78 e método de uso dos mesmos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B06J | Correction of requirement [chapter 6.10 patent gazette] |
Free format text: REPUBLICACAO DO PARECER 6.1 NOTIFICADO NA RPI NO 2852. |
|
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |